StreetAlpha.app
Home › Stocks › AMPH

Amphastar Pharmaceuticals, Inc. (AMPH)

Healthcare
$29.10
▼ −0.24%
LAST CLOSE · NOV 17

Amphastar makes injectable, inhaled and nasal medicines, including generics and proprietary products, sold to patients and healthcare providers. It last closed at $29.10 on Nov 17, down 0.24% on the day.

AI Auto Pilots
Is AMPH in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$745.8M
+3.1% vs a year ago
Net income
$99.0M
−11.3% vs a year ago
EPS (diluted)
$2.18
−3.5% vs a year ago
Free cash flow
$139.0M
18.6% margin
Valuation
Market cap
$1.2B
42.7M shares
P/E
13.3
Price over 12 month EPS
Price to sales
1.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$204.6M
At Sep 30
Shareholder equity
$814.6M
Buybacks
$95.7M
Last 12 months
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $437.8M$437.8MFY2021FY2022: $499.0M$499.0MFY2022FY2023: $644.4M$644.4MFY2023FY2024: $732.0M$732.0MFY2024FY2025: $719.9M$719.9MFY2025

From AMPH's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Last report
Nov 5
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Hold
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Hold
1firm
0 Buy1 Hold0 Sell
Only 1 firm rated AMPH in the past 90 days, not enough for a consensus
Average 12-month target
$25.00
▼ 14.1% downside

Based on 1 analyst who set a price target on AMPH in the past 90 days. The average target is $25.00, with a high of $25.00 and a low of $25.00, compared with the last close of $29.10.

Low $25.00Avg $25.00High $25.00
Blue marker: last close $29.10
Highest target$25.00
Average target$25.00
Lowest target$25.00
Latest rating changes
Wells FargoTarget raised
Nov 6Hold$20 → $25
Piper SandlerMaintained
Aug 7Hold$20
Wells FargoTarget raised
Aug 7Hold$19 → $20
B of A SecuritiesDowngrade
Jun 29Sell$20
BarclaysMaintained
Jun 3Hold$20
DateFirmActionRatingPrice target
Nov 6Wells FargoTarget raisedHold$20 → $25
Aug 7Piper SandlerMaintainedHold$20
Aug 7Wells FargoTarget raisedHold$19 → $20
Jun 29B of A SecuritiesDowngradeSell$20
Jun 3BarclaysMaintainedHold$20
Loading…

Technical Analysis

AMPH · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought

The stock is 5% above its 20 day and 10% above its 50 day average. It is 23% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 64), near overbought. The nearest support is the Pivot at $28.90, and the nearest resistance the Pivot R1 at $29.58.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityNormal, 3.5%/day
Key levels
$30.3952 week high+4.4%
$30.39Swing high (Nov 6)+4.4%
$29.58Pivot R1+1.6%
$29.10Last close
$28.90Pivot−0.7%
$28.41Pivot S1−2.4%
$27.5620 day average−5.3%
$26.2050 day average−10.0%
$25.03Swing low (Oct 6)−14.0%
$23.39100 day average−19.6%
$22.38200 day average−23.1%
$16.6552 week low−42.8%
Indicators
RSI (14)64.41Strong, overbought above 70Neutral
MACD0.96Above its signal lineBullish
Stochastic74.4Middle of its rangeNeutral
ADX (14)43.3Strong uptrend
Williams %R-32.7Oversold below −80, overbought above −20Neutral
CCI (20)70.3Oversold below −100, overbought above 100Neutral
Rate of change+7.3%Change over 10 sessionsBullish
ATR (14)$1.02Typical daily range, 3.5% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for AMPH

What happened before

See how AMPH did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow AMPH usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How AMPH has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in AMPH in the last 90 days.

Loading…

See today’s whale options flow across the market →

AMPH Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ●109 buying vs 97 selling
  • ▲Held by funds +2.0 pts
  • ▲Funds holding +16
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding227211+7.6%
In funds' top 1020–
Held by funds68.4%66.5%+2.0 pts
New / increased37 / 7231 / 63+16.0%
Reduced / sold out74 / 2375 / 33−10.2%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See AMPH institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AMPH is in one of them and how their past AMPH trades turned out.

AMPH in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered AMPH in an article yet. Here's the latest on the wider market.

AMPH Congress Trades

All congress trades →
Trades, 12 months
1
Buys
0
0%
Sells
1
100%
People
1
Last filed Jul 1
Who traded AMPH · since 2026
Latest 1 filing
$15K – $50KTraded May 15, 2026Filed Jul 1, 2026
PersonTypeAmountTradedFiledDelay
Donald J TrumpExecutive branchSell$15K – $50KMay 15, 2026Jul 1, 202647 d

Members of Congress and senior officials report trades up to 45 days later, as dollar ranges. Filings show a trade happened, not why. Not investment advice.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals is a pharmaceutical company based in Rancho Cucamonga, California. It develops, manufactures and sells injectable, inhalation and nasal drug products, including generic and proprietary medicines, as well as active pharmaceutical ingredients. Its best-known products include BAQSIMI, a nasal glucagon for severe low blood sugar in people with diabetes, and Primatene MIST, an asthma inhaler sold without a prescription. Its customers include patients and healthcare providers in the United States and in international markets.

Headquarters
Rancho Cucamonga, CA